You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

The Journal of Alzheimer’s Disease Is Happy to Announce the Appointment of Paula I. Moreira, PhD, as Co-Editor-in-Chief of the Journal

jad-97-jad249000-g001.jpg

Dr. Moreira is an Associate Professor of Physiology at the Faculty of Medicine, University of Coimbra and leads the MitoBD – Mitochondria in Brain Disorders research group at the Center for Neuroscience and Cell Biology, University of Coimbra (CNC-UC), Portugal. Moreira’s group is mainly interested in elucidating the critical role of mitochondria (energy, homeostasis, and signals) in brain changes associated with metabolic and neurodegenerative diseases, with a special emphasis on Alzheimer’s disease. Her research group is also interested in exploring the preventive and therapeutic potential of pharmacological and nonpharmacological strategies, such as mitochondrial modulators and hypoxic (pre)conditioning. Moreira was the recipient of the Stimulus to Research prize, in 2003, supported by the Calouste Gulbenkian Foundation, the L’Oréal for Women in Science Award, in 2008, supported by L’Oréal Portugal/UNESCO/FCT and, in 2023, the RFS Award in Science for Antioxidants & Redox Signaling journal, supported by Mary Ann Liebert, Inc., in collaboration with the Rosalind Franklin Society.

Paula Moreira has been an Associate Editor of JAD since 2004, served as a Regional Editor in 2016 and as Deputy Editor from 2017 to 2023. She published and reviewed many articles for the journal. She joins the Editor-in-Chief George Perry to help consolidate JAD as a reference journal in the field of Alzheimer’s disease and related dementia. Moreira is committed to support the growth of JAD as a top repository of cutting-edge basic, translational, and clinical research. The accelerated pace at which new knowledge about Alzheimer’s disease pathophysiology builds up together with the fast development of diagnostic and treatment strategies requires an effective and fast knowledge transfer between the scientific and clinical communities. JAD, as the leading journal in this field, is the primary “voice” of the most innovative advancements in Alzheimer’s disease.

George Perry, Editor-in-Chief of JAD said, “We are honored by Dr. Moreira’s acceptance of this new role and the leadership she brings to JAD. Dr. Moreira is a leading scientist with years of innovative insights, mentorship and collegiality focused on solving the puzzle of Alzheimer’s disease.”